Evercyte and TAmiRNA to highlight advances in EV characterization at Precision EV forum

Vienna, Austria: –Biotech and diagnostic innovator TAmiRNA with its companion member Evercyte of the EVscale^® consortium will form a prominent joint presence at the upcoming Precision EV Forum in the English university city of Cambridge.

TAmiRNA, attending in company with fellow Vienna-based innovator Evercyte, will have a tabletop exhibition stand at the Cripps Court Conference Centre that showcase its advanced multiomic capabilities in characterization of RNA cargo (small and long RNAs) EVs for biomarker discovery.

Innovative technologies

Also featured will be Evercyte’s extensive EV therapeutics development portfolio of telomerized MSCs derived from different tissues to produce clinical-grade EVs. Together, these form key components that can be leveraged by fellow Austrian company Phoenestra’s innovative bioreactor technology to realize the EVscale vision of more rapid discovery and sustainable continuous manufacturing.

This is a return to the Precision EV Forum for TAmiRNA, who also featured at the inaugural Extracellular Vesicles Forum in 2023.

TAmiRNA has submitted a poster contribution to the meeting dealing with different aspects and applications of its miND® bioinformatic data analysis pipeline and the interactive omics-data reports that it can generate for more rapid discovery.

Evercyte contributes a poster highlighting the suitability of Evercyte’s telomerized cell lines for EV production.

Rapid precision medicine discovery

The TAmiRNA and Evercyte team in Cambridge will include TAmiRNA CEO Dr. Matthias Hackl and Evercyte COO and CSO Dr. Regina Grillari.

Dr. Hackl commented: “Together with Evercyte, we are bringing a great deal to this meeting that is highly relevant to application of EVs in precision medicine. TAmiRNA’s unique EV characterization services and advanced transcriptomic analysis of both small (microRNAs) and larger (mRNA, long non-coding RNA) RNAs, using our NextGen sequencing miND^® platform with its panel of spike-ins, is of huge potential benefit to researchers working on applications of EVs as biomarkers or therapies.”

Dr. Grillari added: “The Forum organizers identify issues such as heterogeneity, characterization, production, and scalability as key challenges in clinical development of EVs. Together with Phoenestra as the EVscale consortium, we have innovative answers in all these fields that make EVscale highly interesting for companies interested in EV drug development as an advanced platform for EV development and production.”

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality RNA profiling of various sample types and offers a fully integrated service from RNA extraction to data analysis. TAmiRNA has optimized its workflows for the comprehensive analysis of EV small and long RNA cargo.

TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

More information available at: www.tamirna.com

About Evercyte GmbH

Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines to produce extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.

Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.

Learn more at: www.evercyte.com

About Precision EV Forum 2024

First hosted in 2023 as the Extracellular Vesicles Forum, the Precision EV Forum is a meeting for the EV and exosomes research community focused on precision medicine, encompassing precise diagnostics and targeted treatment.

The 2024 Precision EV Forum will be a two-day event opening October 23 at the Cripps Court Conference Centre in the historic English university city of Cambridge.

The 2024 Forum will focus on translational aspects of EV research and development that will have clinical applications, including Biomarkers, Diagnostics, Therapeutics, Drug Delivery and Regenerative Medicine. Organizers hope knowledge exchange will help overcome bottlenecks in the clinical development of EVs, such as Regulatory Approval, Heterogeneity, Characterization, Production and Scalability.

The event is organized by the Precision Medicine Forum in partnership with Arch Events with further information at https://www.precisionmedicineforum.com/our-conferences_trashed/extracellular-vesicles-2024/

Resources

Click on TAmiRNA EV characterization services for further information.
Click on miND® pipeline for small RNA-sequencing to learn more about NextGen multiomic characterization.
Click on Evercyte EV Cell Factories to learn more.
Click on Evercyte off-the-shelf EVs for further information.
Click on EV enrichment, purification and characterization for further services.